Treatment outcome by prognostic factors
| Prognostic factors . | n (%) . | 5-year EFS, estimate ± SE, % . | P (log-rank test) . | CIR at 5 years, estimate ± SE, % . | P (Gray’s test) . |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 107 (53.5) | 92.5 ± 2.5 | .12 | 6.5 ± 2.4 | .77 |
| Female | 93 (46.5) | 86.0 ± 3.6 | 7.5 ± 2.7 | ||
| Age | |||||
| 1 to <5 years | 133 (66.5) | 88 ± 2.8 | .31 | 7.5 ± 2.3 | .66 |
| ≥5 years | 67 (33.5) | 92.5 ± 3.2 | 5.9 ± 2.9 | ||
| White blood cells, 109/L | |||||
| <10 | 140 (70) | 90.7 ± 2.5 | .39 | 7.1 ± 2.2 | .91 |
| 10-50 | 60 (30) | 86.7 ± 4.4 | 6.7 ± 3.2 | ||
| CNS disease* | |||||
| CNS 1 | 184 (92) | 90.2 ± 2.2 | .26 | 6 ± 1.7 | .051 |
| Traumatic tap | 16 (8) | 81.3 ± 9.8 | 18.7 ± 10.1 | ||
| DNA index | |||||
| ≥1.16 | 61 (30.5) | 95.1 ± 2.8 | .092 | 4.9 ± 2.8 | .46 |
| <1.16 | 139 (69.5) | 87.1 ± 2.8 | 7.9 ± 2.3 | ||
| t(12;21)/ETV6-RUNX1 | |||||
| Present | 85 (42.5) | 87.1 ± 3.6 | .36 | 10.6 ± 3.4 | .09 |
| Absent | 115 (57.5) | 91.3 ± 2.6 | 4.3 ± 1.9 | ||
| Favorable double trisomy† | |||||
| Positive | 49 (24.5) | 95.9 ± 2.8 | .099 | 2.0 ± 2.0 | .12 |
| Negative | 151 (75.5) | 87.4 ± 2.7 | 8.6 ± 2.3 | ||
| MRD at day 19 | |||||
| Undetectable | 171 (85.5) | 91.2 ± 2.2 | .059 | 5.3 ± 1.7 | .02 |
| Detectable, 0.001% to <0.01% | 29 (14.5) | 79.3 ± 7.5 | 17.2 ± 7.2 | ||
| L-asparaginase hypersensitivity | |||||
| No | 155 (77.5) | 88.4 ± 2.6 | .33 | 7.1 ± 2.1 | .91 |
| Yes | 45 (22.5) | 93.3 ± 3.7 | 6.7 ± 3.8 |
| Prognostic factors . | n (%) . | 5-year EFS, estimate ± SE, % . | P (log-rank test) . | CIR at 5 years, estimate ± SE, % . | P (Gray’s test) . |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 107 (53.5) | 92.5 ± 2.5 | .12 | 6.5 ± 2.4 | .77 |
| Female | 93 (46.5) | 86.0 ± 3.6 | 7.5 ± 2.7 | ||
| Age | |||||
| 1 to <5 years | 133 (66.5) | 88 ± 2.8 | .31 | 7.5 ± 2.3 | .66 |
| ≥5 years | 67 (33.5) | 92.5 ± 3.2 | 5.9 ± 2.9 | ||
| White blood cells, 109/L | |||||
| <10 | 140 (70) | 90.7 ± 2.5 | .39 | 7.1 ± 2.2 | .91 |
| 10-50 | 60 (30) | 86.7 ± 4.4 | 6.7 ± 3.2 | ||
| CNS disease* | |||||
| CNS 1 | 184 (92) | 90.2 ± 2.2 | .26 | 6 ± 1.7 | .051 |
| Traumatic tap | 16 (8) | 81.3 ± 9.8 | 18.7 ± 10.1 | ||
| DNA index | |||||
| ≥1.16 | 61 (30.5) | 95.1 ± 2.8 | .092 | 4.9 ± 2.8 | .46 |
| <1.16 | 139 (69.5) | 87.1 ± 2.8 | 7.9 ± 2.3 | ||
| t(12;21)/ETV6-RUNX1 | |||||
| Present | 85 (42.5) | 87.1 ± 3.6 | .36 | 10.6 ± 3.4 | .09 |
| Absent | 115 (57.5) | 91.3 ± 2.6 | 4.3 ± 1.9 | ||
| Favorable double trisomy† | |||||
| Positive | 49 (24.5) | 95.9 ± 2.8 | .099 | 2.0 ± 2.0 | .12 |
| Negative | 151 (75.5) | 87.4 ± 2.7 | 8.6 ± 2.3 | ||
| MRD at day 19 | |||||
| Undetectable | 171 (85.5) | 91.2 ± 2.2 | .059 | 5.3 ± 1.7 | .02 |
| Detectable, 0.001% to <0.01% | 29 (14.5) | 79.3 ± 7.5 | 17.2 ± 7.2 | ||
| L-asparaginase hypersensitivity | |||||
| No | 155 (77.5) | 88.4 ± 2.6 | .33 | 7.1 ± 2.1 | .91 |
| Yes | 45 (22.5) | 93.3 ± 3.7 | 6.7 ± 3.8 |